Cargando…

Glucosamine as a Treatment for Osteoarthritis: What If It’s True?

No disease-modifying treatments are currently available for osteoarthritis (OA). While many therapeutic approaches are now being investigated it is ethical to resort to alternative solutions as that we already possess. There are many reasons for thinking that, at sufficiently high doses, glucosamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Conrozier, Thierry, Lohse, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968913/
https://www.ncbi.nlm.nih.gov/pubmed/35370756
http://dx.doi.org/10.3389/fphar.2022.820971
_version_ 1784679146322919424
author Conrozier, Thierry
Lohse, Thomas
author_facet Conrozier, Thierry
Lohse, Thomas
author_sort Conrozier, Thierry
collection PubMed
description No disease-modifying treatments are currently available for osteoarthritis (OA). While many therapeutic approaches are now being investigated it is ethical to resort to alternative solutions as that we already possess. There are many reasons for thinking that, at sufficiently high doses, glucosamine (GlcN) sulphate possesses a clinically relevant effect on OA pain. Wide inter-individual variations in the symptomatic effects of GlcN are explained by the extreme variability of its bioavailability. In studies evaluating its structure-modifying effect, GlcN was more effective than placebo in reducing the rate of joint space narrowing in patients with knee OA. More recent data suggest that GlcN may be effective in the primary prevention of OA in sportsmen. There is no controversy concerning the safety of GlcN which does not differ to that of placebo. Several studies have recently revealed an unexpected effect of GlcN on cardiovascular mortality. After adjusting for confounding factors, the regular consumption of GlcN correlated with a 27% reduction in mortality and a 58% reduction in deaths from cardiovascular causes. These data confirm animal studies demonstrating a protective effect of GlcN against cancer and cardiovascular diseases due to modulation of the O-GlcNAcylation pathway. Disorders in O-GlcNAcylation are involved in diabetes, obesity and cancers, which all feature chronic low-grade inflammation (CLGI). By regulating CLGI, GlcN may be beneficial to the symptoms of OA, its outcome and to that of the concomitant chronic pathologies, making GlcN as a valuable candidate for the treatment of OA in patients with metabolic syndrome, diabetes or cardiovascular diseases.
format Online
Article
Text
id pubmed-8968913
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89689132022-04-01 Glucosamine as a Treatment for Osteoarthritis: What If It’s True? Conrozier, Thierry Lohse, Thomas Front Pharmacol Pharmacology No disease-modifying treatments are currently available for osteoarthritis (OA). While many therapeutic approaches are now being investigated it is ethical to resort to alternative solutions as that we already possess. There are many reasons for thinking that, at sufficiently high doses, glucosamine (GlcN) sulphate possesses a clinically relevant effect on OA pain. Wide inter-individual variations in the symptomatic effects of GlcN are explained by the extreme variability of its bioavailability. In studies evaluating its structure-modifying effect, GlcN was more effective than placebo in reducing the rate of joint space narrowing in patients with knee OA. More recent data suggest that GlcN may be effective in the primary prevention of OA in sportsmen. There is no controversy concerning the safety of GlcN which does not differ to that of placebo. Several studies have recently revealed an unexpected effect of GlcN on cardiovascular mortality. After adjusting for confounding factors, the regular consumption of GlcN correlated with a 27% reduction in mortality and a 58% reduction in deaths from cardiovascular causes. These data confirm animal studies demonstrating a protective effect of GlcN against cancer and cardiovascular diseases due to modulation of the O-GlcNAcylation pathway. Disorders in O-GlcNAcylation are involved in diabetes, obesity and cancers, which all feature chronic low-grade inflammation (CLGI). By regulating CLGI, GlcN may be beneficial to the symptoms of OA, its outcome and to that of the concomitant chronic pathologies, making GlcN as a valuable candidate for the treatment of OA in patients with metabolic syndrome, diabetes or cardiovascular diseases. Frontiers Media S.A. 2022-03-17 /pmc/articles/PMC8968913/ /pubmed/35370756 http://dx.doi.org/10.3389/fphar.2022.820971 Text en Copyright © 2022 Conrozier and Lohse. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Conrozier, Thierry
Lohse, Thomas
Glucosamine as a Treatment for Osteoarthritis: What If It’s True?
title Glucosamine as a Treatment for Osteoarthritis: What If It’s True?
title_full Glucosamine as a Treatment for Osteoarthritis: What If It’s True?
title_fullStr Glucosamine as a Treatment for Osteoarthritis: What If It’s True?
title_full_unstemmed Glucosamine as a Treatment for Osteoarthritis: What If It’s True?
title_short Glucosamine as a Treatment for Osteoarthritis: What If It’s True?
title_sort glucosamine as a treatment for osteoarthritis: what if it’s true?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968913/
https://www.ncbi.nlm.nih.gov/pubmed/35370756
http://dx.doi.org/10.3389/fphar.2022.820971
work_keys_str_mv AT conrozierthierry glucosamineasatreatmentforosteoarthritiswhatifitstrue
AT lohsethomas glucosamineasatreatmentforosteoarthritiswhatifitstrue